Comparative Pharmacology
Head-to-head clinical analysis: CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE versus DIURIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE versus DIURIL.
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE vs DIURIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan cilexetil is a prodrug that is hydrolyzed to candesartan, an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis and further lowering blood pressure.
Inhibits sodium reabsorption in the distal convoluted tubule by blocking the sodium-chloride symporter, leading to increased excretion of sodium, chloride, and water.
1 tablet (candesartan cilexetil 16 mg/hydrochlorothiazide 12.5 mg) orally once daily. Maximum dose: 1 tablet (32 mg/25 mg) once daily.
Adults: 500 mg to 1000 mg orally once or twice daily; maximum 2000 mg per day.
None Documented
None Documented
Candesartan: Terminal t1/2 ~9 hours (linear); clinically, once-daily dosing provides 24-hour antihypertensive effect. Hydrochlorothiazide: Terminal t1/2 ~6-15 hours (averaging 10 hours), prolonged in renal impairment.
Terminal elimination half-life is 6-15 hours (mean 10 hours). In renal impairment, half-life can exceed 24 hours.
Candesartan: ~33% renal, ~67% biliary/fecal as unchanged drug and inactive metabolites. Hydrochlorothiazide: ≥95% renal as unchanged drug.
Primarily renal (90-95% excreted unchanged via glomerular filtration and tubular secretion); minimal biliary/fecal (<5%).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic